Correlation Between Inozyme Pharma and Exicure

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Exicure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Exicure into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Exicure, you can compare the effects of market volatilities on Inozyme Pharma and Exicure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Exicure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Exicure.

Diversification Opportunities for Inozyme Pharma and Exicure

0.53
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Inozyme and Exicure is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Exicure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exicure and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Exicure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exicure has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Exicure go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Exicure

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Exicure. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 1.95 times less risky than Exicure. The stock trades about -0.29 of its potential returns per unit of risk. The Exicure is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  1,954  in Exicure on December 21, 2024 and sell it today you would lose (598.00) from holding Exicure or give up 30.6% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Inozyme Pharma  vs.  Exicure

 Performance 
       Timeline  
Inozyme Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Exicure 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Exicure has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Exicure is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Inozyme Pharma and Exicure Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inozyme Pharma and Exicure

The main advantage of trading using opposite Inozyme Pharma and Exicure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Exicure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exicure will offset losses from the drop in Exicure's long position.
The idea behind Inozyme Pharma and Exicure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Complementary Tools

Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites